Device-specific quality of life: results from the ATLAS trial—avoid transvenous leads in appropriate subjects.

Aims Patient-reported outcomes (PROs) provide important insights into patients' acceptance of their medical devices. Avoid Transvenous Leads in Appropriate Subjects (ATLAS), a randomized, multi-centre, open-label clinical trial, recently reported fewer perioperative complications in subcutaneous imp...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Cardiovascular Nursing Vol. 23; no. 8; pp. 877 - 886
Autores principales: Carroll, Sandra L, Mondésert, Blandine, Krahn, Andrew D, Bashir, Jamil G, Fisher, Kathryn, Nair, Kalpana, Healey, Jeff S
Formato: pictorial research tables/charts Journal Article
Publicado: Oxford University Press / USA Nov2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=181970294&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 181970294
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14745151
        KJC
      jtl: European Journal of Cardiovascular Nursing
      issn: 14745151
      maglogo: N
    pubinfo:
      dt: Nov2024
      vid: 23
      iid: 8
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        181970294
        181970294
        181970294
        10.1093/eurjcn/zvae067
        181970294
      ppf: 877
      ppct: 9
      formats:
      tig:
        atl: Device-specific quality of life: results from the ATLAS trial—avoid transvenous leads in appropriate subjects.
      aug:
        au:
          Carroll, Sandra L
          Mondésert, Blandine
          Krahn, Andrew D
          Bashir, Jamil G
          Fisher, Kathryn
          Nair, Kalpana
          Healey, Jeff S
        affil: School of Nursing, McMaster University, 1280 Main Street West, HSC 2J17, Hamilton, ON, Canada L8S 4K1
      sug:
        subj:
          Patient-Reported Outcomes Evaluation
          Quality of Life Evaluation
          Defibrillators, Implantable Adverse Effects
          Postoperative Complications Prevention and Control
          Human
          Male
          Female
          Surveys
          Analysis of Variance
          Pain Measurement
          Descriptive Statistics
          Comparative Studies
          Linear Regression
          Data Analysis Software
          Confidence Intervals
          Exploratory Research
          Short Form-36 Health Survey (SF-36)
          Scales
          Male
          Female
      ab: Aims Patient-reported outcomes (PROs) provide important insights into patients' acceptance of their medical devices. Avoid Transvenous Leads in Appropriate Subjects (ATLAS), a randomized, multi-centre, open-label clinical trial, recently reported fewer perioperative complications in subcutaneous implantable cardioverter defibrillator (S-ICD) compared with transvenous ICD (TV-ICD) patients. This study reports PROs, including device-specific and generic quality of life (QOL), from the ATLAS trial. Methods and results Device-specific QOL was the primary PRO using the Florida Patient Acceptance Survey (FPAS) at 1 and 6 months' post-implantation. Secondary outcomes included generic QOL using the Medical Outcomes Survey (SF-36) pre-implant and 6 months' post-implantation. The FPAS and SF-36 were analysed using analysis of covariance. Pain measured using a Numeric Rating Scale, at 1 and 6 months, anaesthetic, body mass index, and within/between differences were analysed using descriptive statistics and mixed-effects linear models. Of the 503 patients randomized in ATLAS, 404 had complete FPAS data to be included in this analysis. Participant characteristics were balanced. There were no significant differences between S-ICD and TV-ICD for the FPAS or SF-36, across time points. Mean total FPAS scores increased from 73.73 (16.09) to 77.05 (16.13) and 74.43 (15.35) to 78.25 (15.88) for S-ICD and TV-ICD, respectively (P < 0.001). Patient-reported outcomes suggested that both devices were associated with good QOL. Conclusion Device-specific and generic QOL were similar between S-ICD and TV-ICD groups up to 6 months' post-implantation, indicating that regardless of device type, both groups reported good device-specific QOL in ATLAS patients. Subcutaneous ICD patients reported higher pain scores at implant, but pain decreased by 6 months. The findings offer evidence that can be included during shared decision-making. The inclusion of patient partners in ATLAS provided an opportunity to measure PROs that were deemed important to patients. Registration ClinialTrials.gov : NCT02881255
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N